Liver targeting of antiviral nucleoside analogues through the asialoglycoprotein receptor

Journal of Viral Hepatitis

Volumn 4, Issue 6, 1997, Pages 363-370

  Fiume, L ^a,e   Di Stefano, G ^a   Busi, C ^a   Mattioli, A ^a   Bonino, F ^b   Torrani Cerenzia, M ^b   Verme, G ^b   Rapicetta, M ^c   Bertini, M ^d   Gervasi, G B ^d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d Laboratori Baldacci   (Italy)

^e Dipartimento di Patologia Sperimentale   (Italy)

Author keywords

Antiviral nucleoside analogues; Asialoglycoprotein receptor; Liver targeting of drugs; Viral hepatitis

Indexed keywords

ALPHA FETOPROTEIN; ANTIVIRUS AGENT; ARABINOGALACTAN; ASIALOFETUIN; ASIALOGLYCOPROTEIN; ASIALOGLYCOPROTEIN RECEPTOR; CELL SURFACE RECEPTOR; DRUG CARRIER; GALACTAN; LACTOSE; LIPOPROTEIN; NUCLEOSIDE; POLYLYSINE; SERUM ALBUMIN; VIDARABINE PHOSPHATE;

ANIMAL; HUMAN; LIVER; METABOLISM; REVIEW;

ALPHA-FETOPROTEINS; ANIMALS; ANTIVIRAL AGENTS; ASIALOGLYCOPROTEIN RECEPTOR; ASIALOGLYCOPROTEINS; DRUG CARRIERS; GALACTANS; HUMANS; LACTOSE; LIPOPROTEINS; LIVER; NUCLEOSIDES; POLYLYSINE; RECEPTORS, CELL SURFACE; SERUM ALBUMIN; VIDARABINE PHOSPHATE;

EID: 0031308726     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.1997.00067.x     Document Type: Review

References (61)

1. Trouet A, Deprez-De Campeneere D, De Duve C. Chemotherapy through lysosomes with a DNA-daunorubicin complex. Nature New Biol 1972; 239:110-112.
2. Barbanti-Brodano G, Fiume L. In vitro effect of a 5-fluorodeoxyuridine albumin conjugate on tumor cells and on peritoneal macrophages. Experientia 1974; 30: 1180-1181.
3. Balboni PG, Minia A, Grossi MP, Barbanti-Brodano G, Mattioli A, Fiume L. Activity of albumin conjugates of 5-fluorodeoxyuridine and cytosine arabinoside on poxviruses as a lysosomotropic approach to antiviral chemotherapy. Nature 1976; 264: 181-183.
4. Morell AG, Irvine RA, Sternlieb I, Scheinberg IH, Ashwell G. Physical and chemical studies on ceruloplasmin. V. Metabolic studies on sialic acid-free ceruloplasmin in vivo. J Biol Chem 1968; 243: 155-159.
5. Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem 1982; 51: 531-534.
6. Fiume L, Mattioli A, Balboni PG et al. Enhanced inhibition of virus DNA synthesis in heptocytes by trifluorothymidine coupled to asialofetuin. FEBS Lett 1979; 103: 47-51.
7. Fiume L, Mattioli A, Busi C et al. Selective inhibition of Ectromelia virus DNA synthesis in hepatocytes by adenine-9-β-D-arabinofuranoside (ara-A) and adenine-β-D-arabinofuranoside 5′-monophosphate (ara-AMP) conjugated to asialofetuin. FEBS Lett 1980; 116: 185-188.
8. Rogers JC, Kornfeld S. Hepatic uptake of proteins coupled to fetuin glycopeptide. Biochem Biophys Res Commun 1971; 45: 622-629.
9. Gregoriadis G, Neerunjun ED. Homing of liposomes to target cells. Biochem Biophys Res Commun 1975; 65: 537-544.
10. Fiume L, Mattioli A, Busi C, Spinosa G, Wieland T. Conjugates of adenine-9-β-D-arabinofuranoside monophosphate (ara-AMP) with lactosaminated homologous albumin are not immunogenic in the mouse. Experientia 1982; 38: 1087-1089.
11. Fiume L, Busi C, Mattioli A, Balboni PG, Barbanti-Brodano G. Hepatocyte targeting of adenine-9-β-D-arabinofuranoside 5′-monophosphate (ara-AMP) coupled to lactosaminated albumin. FEBS Lett 1981; 129: 261-264.
12. Fiume L, Bassi B, Busi C, Mattioli A, Spinosa G. Drug targeting in antiviral chemotherapy. A chemically stable conjugate of 9-β-D-arabinofuranosyladenine 5′-monophosphate with lactosaminated albumin accomplishes a selective delivery of the drug to liver cells. Biochem Pharmacol 1986; 35: 967-972.
13. Schwartz BA, Gray GR. Proteins containing reductively aminated disaccharides. Synthesis and chemical characterization. Arch Biochem Biophys 1977; 181: 542-549.
14. Wilson G. Effect of reductive lactosamination on the hepatic uptake of bovine pancreatic ribonuclease A dimer. J Biol Chem 1978; 253: 2070-2072.
15. Krantz MJ, Holtzman NA, Stowell CP, Lee YC. Attachment of thioglycosides to proteins: enhancement of liver membrane binding. Biochemistry 1976; 15: 3963-3968.
16. Fiume L, Busi C, Preti P, Spinosa G. Conjugates of ara-AMP with lactosaminated albumin: a study on their immunogeneticity in mouse and rat. Cancer Drug Delivery 1987; 4: 145-150.
17. Jacyna MR, Thomas HC. Antiviral therapy: Hepatitis B. Br Med Bull 1990; 46: 368-382.
18. Fiume L, Bassi B, Bongini A. Conjugates of 9-β-D-arabinofuranosyladenine 5′-monophosphate (ara-AMP) with lactosaminated albumin: Characterization of the drug-carrier bonds. Pharm Acta Helv 1988; 63: 137-139.
19. Fiume L, Balboni PG, Bassi B, Busi C, Mattioli A, Spinosa G. 9-β-D-arabinofuranosyl-adenine 5′-monophosphate coupled to lactosaminated albumin is not metabolized in mouse bloodstream. Pharm Acta Helv 1986; 61: 342-344.
20. Fiume L, Busi C, Corzani S, Di Stefano G, Gervasi GB, Mattioli A. Organ distribution of a conjugate of adenine arabinoside monophosphate with lactosaminated albumin in rat. J Hepatol 1994; 20: 681-682.
21. Fiume L, Busi C, Di Stefano G, Mattioli A. Targeting of antiviral drugs to the liver using glycoprotein carriers. Adv Drug Deliv Rev 1994; 14: 51-65.
22. Ponzetto A, Fiume L, Forzani B et al. Adenine arabinoside monophosphate and acyclovir monophosphate coupled to lactosaminated albumin reduce woodchuck hepatitis virus viremia at doses lower than do the unconjugated drugs. Hepatology 1991; 14: 16-24.
23. Fiume L, Torrani Cerenzia MR, Bonino F et al. Inhibition of hepatitis B virus replication by vidarabine monophosphate conjugated with lactosaminated serum albumin. Lancet 1988; 2: 13-15.
24. Torrani Cerenzia MR, Fiume L, Busi C et al. Inhibition of hepatitis B virus replication by adenine arabinoside monophosphate coupled to lactosaminated albumin. Efficacy and minimal effective dose. J Hepatol 1994; 20: 307-309.
25. Torrani-Cerenzia MR, Fiume L, De Bernardi Venon W et al. Adenine arabinoside monophosphate coupled to lactosaminated albumin, administered for 4 weeks to patients with chronic type B hepatitis, decreased viremia without producing significant side effects. Hepatology 1996; 23: 657-661.
26. Hoofnagle JH, Hanson RG, Minuk GY et al. Randomized controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis. Gastroenterology 1984; 86: 150-157.
27. Renoldi A, Maraschin R, Conz A et al. 4-week intravenous toxicity study in Cynomolgus monkeys treated with L-HSA-ara-AMP. RBM (Istituto di Ricerche Biomediche Antoine Marxer, Ivrea, Italy) 1990; Exp. no. 890520.
28. Hafkin B, Pollard RB, Tiku ML, Robinson WS, Merigan TC. Effects of interferon and adenine arabinoside treatment of hepatitis B virus infection on cellular immune responses. Antimicrob Agents Chemother 1979; 16: 781-787.
29. Fiume L, Bassi B, Busi C, Mattioli A, Spinosa G, Faulstich H. Galactosylated poly(L-lysine) as a hepatotropic carrier of 9-β-D-arabinofuranosyladenine 5′-monophosphate. FEBS Lett 1986; 203: 203-206.
30. Groman EV, Enriquez PM, Jung C, Josephson L. Arabinogalactan for hepatic drug delivery. Bioconjugate Chem 1994; 5: 547-556.
31. Marcellin P, Poureau M, Loriot MA et al. Adenine arabinoside 5′-monophosphate in patients with chronic hepatitis B: comparison of the efficacy in patients with high and low viral replication. Gut 1995; 36: 422-426.
32. Fiume L, Di Stefano G, Busi C, Mattioli A. A conjugate of lactosaminated poly-L-lysine with adenine arabinoside monophosphate, administered to mice by intramuscular route, accomplishes a selective delivery of the drug to the liver. Biochem Pharmacol 1994; 47: 643-650.
33. Di Stefano G, Busi C, Mattioli A, Fiume L. Selective delivery to the liver of antiviral nucleoside analogs coupled to a high molecular mass lactosaminated poly-L-lysine and administered to mice by intramuscular route. Biochem Pharmacol 1995; 49: 1769-1775.
34. Fiume L, Di Stefano G, Busi C et al. Inhibition of wood-chuck hepatitis virus replication by adenine arabinoside monophosphate coupled to lactosaminated poly-L-lysine and administered by intramuscular route. Hepatology 1995; 22: 1072-1077.
35. Katchalski E, Sela M, Silman HI, Berger A. Polyamino acids as protein models. In: Neurath H, ed. The Protein. Composition, Structure and Function. Vol. 2, 2nd edn. New York: Academic Press, 1964: 405-581.
36. Fiume L, Di Stefano G, Busi C et al. Hepatotropic conjugate of adenine arabinoside monophosphate with lactosaminated poly-L-lysine. Synthesis of the carrier and pharmacological properties of the conjugate. J Hepatol 1997; 26: 253-259.
37. Fiume L, Betts MC, Busi C et al. The pathogenesis of vacuoles produced in rat and mouse liver cells by a conjugate of adenine arabinoside monophosphate with lactosaminated albumin. J Hepatol 1992; 15: 314-322.
38. Brillanti S, Garson J, Foli M et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994; 107: 812-817.
39. Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol 1995; 23 (suppl 2): 8-12.
40. Main J. Future studies of combination therapy for chronic hepatitis C: optimizing response rates for each hepatitis C population. J Hepatol 1995; 23 (suppl 2): 32-36.
41. Lai MY, Kao JH, Yang PM et al. Long term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996; 111: 1307-1312.
42. Schalm SW, Hansen BE, Chemello L et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patients from European centers. J Hepatol 1997; 26: 961-966.
43. 14C-ribavirin: distribution and pharmacokinetic studies in rats, baboons and man. In: Smith RA, Kirkpatrick W, eds. Ribavirin: A Broad Spectrum Antiviral Agent. New York: Academic Press, 1980: 83-98.
44. Laskin OL, Longstreth JA, Hart CC et al. Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome. Clin Pharmacol Ther 1987; 41: 546-555.
45. Di Bisceglie AM, Bacon BR, Kleiner DE, Hoofnagle H. Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. J Hepatol 1994; 21: 1109-1112.
46. Fiel MI, Guido M, Thung SN et al. Hepatic iron deposition during ribavirin therapy of chronic hepatitis C. Hepatology 1995; 290A: abstract 736.
47. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology 1997; 25: 759-768.
48. Di Stefano G, Colonna FP, Bongini A, Busi C, Mattioli A, Fiume L. Ribavirin conjugated with lactosaminatcd poly-L-lysine: selective delivery to the liver and increased antiviral activity in mice with viral hepatitis. Biochem Pharmacol 1997; 54: 357-363.
49. Attie AD, Pittman RC, Steinberg D. Metabolism of native and of lactosylated human low density lipoprotein: evidence for two pathways for catabolism of exogenous proteins in rat hepatocytes. Proc Natl Acad Sci USA 1980; 77: 5923-5927.
50. Bijsterbosch MK, van Berkel TJC. Native and modified lipoproteins as drug delivery systems. Adv Drug Del Rev 1990; 5: 231-251.
51. Bijsterbosch MK, Schouten D, van Berkel TJC. Synthesis of the dioleoyl derivative of iododeoxyuridine and its incorporation into reconstituted high density lipoprotein particles. Biochemistry 1994; 33: 14073-14080.
52. Enriquez PM, Jung C, Josephson L, Tennant BC. Conjugation of adenine arabinoside 5′-monophosphate to arabinogalactan: synthesis, characterization, and antiviral activity. Bioconjugate Chem 1995; 6: 195-202.
53. Fiume L, Mattioli A, Spinosa G. Distribution of a conjugate of 9-β-D-arabinofuranosyladenine 5′-monophosphate (ara-AMP) with lactosaminated albumin in parenchymal and sinusoidal cells of rat liver. Cancer Drug Deliv 1987; 4: 11-16.
54. Kruse H, McMaster PD. The distribution and storage of blue antigenic azoproteins in the tissues of mice. J Exp Med 1949; 90: 425-445.
55. Derenzini M, Fiume L, Marinozzi V, Mattioli A, Montanaro L, Sperti S. Pathogenesis of liver necrosis produced by amanitin-albumin conjugates. Lab Invest 1973; 29: 150-158.
56. Marshall JS, Williams S, Jones P. Serum desialylated glycoproteins in patients with hepatobiliary dysfunction. J Lab Clin Med 1978; 92: 30-37.
57. Sawamura T, Nakada H, Hazama H, Shiozaki Y, Sameshima Y, Tashiro Y. Hypersialoglycoproteinemia in patients with chronic liver diseases and/or liver cell carcinoma. Asialoglycoprotein receptor in cirrhosis and liver cell carcinoma. Gastroenterology 1984; 87: 1217-1221.
58. Burgess JB, Baenzinger JU, Brown W. Abnormal surface distribution of the human asialoglycoprotein receptor in cirrhosis. Hepatology 1992; 15: 702-706.
59. 3H]Raffinose, a novel radioactive label for determining organ sites of catabolism of protein in circulation. J Biol Chem 1979; 254: 3547-3553.
60. Luscombe CA, Locarnini SA. The mechanism of action of antiviral agents in chronic hepatitis B. Viral Hep Rev 1996; 2: 1-35.
61. Luscombe C, Pedersen J, Uren E, Locarnini S. Long-term ganciclovir chemotherapy for congenital duck hepatitis B virus infection in vivo: effect on intrahepatic-viral DNA, RNA, and protein expression. Hepatology 1996; 24: 766-773.